From January 23rd to 24th, the 13th Charity Festival and 2023esg Impact Annual Conference kicked off in Beijing. At the meeting, Antengene successfully won two annual awards, the "2023 Responsible Brand Award" and the "Corporate Social Responsibility Industry Model Award" for its years of active practice in medical public welfare and outstanding achievements in the field of drug research and development.
"2023 Responsible Brand Award" and "Corporate Social Responsibility Industry Model Award"
China Charity Festival was established in 2011. It is the first domestic festival named after "charity" jointly initiated by mass media, aiming to promote the spirit of public welfare, Promote public welfare activities and build a platform for in-depth multi-party dialogue, cooperation and communication. After thirteen years of exploration and practice, the Charity Festival has become the most influential annual event in the field of charity in China.
In March 2023, Antengene helped launch the "New Hope·Creation of Miracles" International Myeloma Care Month disease science popularization series hosted by Kangmeng Charity Foundation for two consecutive years. The event focused on "patients with first relapse of multiple myeloma" and gathered 32 authoritative experts in the field of blood to conduct a total of 12 online science popularization live broadcasts. It was simultaneously disseminated on a full digital platform in various forms such as patient stories, comics, pictures and texts, etc. to help The majority of patients and their families have established a basic understanding of standardized diagnosis and treatment methods after myeloma relapse, which has enhanced their confidence in treatment and life.
While actively participating in medical public welfare undertakings, Antengene is also rapidly promoting the clinical application of innovative drugs, striving to benefit people's livelihood and give back to society with development results. Since its establishment, Antengene has focused on the huge medical needs for diseases that still exist in the Asia-Pacific and even the world, and has established a research and development pipeline of 9 oncology drug assets from clinical to commercialization stages. Among them, 6 products have global rights and 3 The product has Asia-Pacific rights. Currently, a number of assets with "first-in-class" and "best-in-class" potential are undergoing clinical studies in more than 100 clinical research centers in Australia, the United States or China. In order to allow more patients to benefit from innovative drugs, the company actively responded to the national medical insurance negotiations and launched its first commercial product - the world's first oral Xpo1 small molecule inhibitor Xivio® (Selinesol tablets) with a new mechanism ) has been successfully included in the 2023 National Medical Insurance Drug List in December 2023, benefiting more Chinese patients and their families. The company is also developing combination therapies targeting Xivio® in a variety of different disease areas to benefit more cancer patients around the world.
Looking back on 2023, Antengene's contributions to social welfare have been repeatedly recognized by all walks of life, and won the "Excellent Case of Big Health Benefiting the People" awarded by the 2023 Xinhua Health Industry and Capital Summit Forum and the 3rd China Lymphoma Patients "CR Guardian Award" awarded by the conference.
Excellent cases of great health and benefiting the people
The "CR Guardian Award" of the 3rd China Lymphoma Patients Conference
Be loyal to the original intention and walk in the future. Antengene will continue to uphold the vision of "doctors without borders, innovation is sustainable", as always, starting from the unmet clinical needs of patients, and bringing high-quality, affordable innovations to patients around the world through practicing the responsibility and responsibility of pharmaceutical companies. Drugs contribute to the development of the industry and society.
Antengene Co., Ltd. (referred to as "Antengene", Hong Kong Stock Exchange stock code: 6996.hk) is a leading biopharmaceutical company driven by research and development and has entered the commercialization stage. With the vision of "continued", Antengene focuses on the early development, clinical research, drug production and commercialization of first-in-class and best-in-class therapies in the field of blood and solid tumors, and is committed to improving the quality of life of patients around the world by providing breakthrough therapies. .
Since 2017, Antengene has established a research and development pipeline of 9 oncology drug assets that have been extended from clinical to commercialization stages. Among them, 6 products have global rights and 3 products have Asia-Pacific rights. The company has obtained 29 clinical approvals (IND) in the United States and multiple Asia-Pacific markets, and submitted 10 new drug marketing applications (NDA). Currently, Xivio® (Selinesol Tablets) has obtained new drug marketing approval in China, Taiwan, Hong Kong, Macau, South Korea, Singapore and Australia.
Forward-looking Statements
The forward-looking statements made in this article relate only to events or information on the date on which the statements are made. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements and unanticipated events, whether as a result of new information, future events or otherwise, after the date on which the forward-looking statements are made. Please read this article carefully and understand that our actual future results or performance may differ materially from expectations. Statements or references in this article regarding the intentions of any Directors or the Company are made as of the date of this article. Any such intentions may change due to future developments. For further discussion of these and other factors that could cause future results to differ materially from any forward-looking statements, please see the additional risks and uncertainties described in our Company's Annual Report for the year ended December 31, 2022 and subsequent filings with Hong Kong Stock exchange filings.
Source: China.com
(Source: Financial and Business Information)
